
Renolife Pharma (India) Private Limited
Manufactures and trades ayurvedic drugs and medicines since 2008.
Manufactures and trades ayurvedic drugs and medicines since 2008.
Renolife Pharma (India) Private Limited (RPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 November 2008 and has a history of 16 years and three months. Its registered office is in Nurani Post, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 1.05 M, as per Ministry of Corporate Affairs (MCA) records.
Tirunilayi Venugopal, Pudugrammam Vaidyanathan, Ajitkumar Warrior, and Four other members serve as directors at the Company.
Nurani Post, Kerala, India
+91-XXXXXXXXXX
-
U52310KL2008PTC023384
023384
Private Limited Indian Non-Government Company
10 Nov 2008
28 Sep 2023
31 Mar 2023
Unlisted
Roc Ernakulam
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kandamkulathy Lazar ![]() | Managing Director | 10-Nov-2008 | Current |
Name | Designation | Appointment Date | Status |
---|---|---|---|
Pudugrammam Vaidyanathan ![]() | Director | 11-Jun-2010 | Current |
Tirunilayi Venugopal ![]() | Director | 11-Jun-2010 | Current |
Ajitkumar Warrior ![]() | Director | 11-Jun-2010 | Current |
Shaji Thuvakkunnon ![]() | Director | 11-Jun-2010 | Current |
Pariyarath Nandakumar ![]() | Director | 11-Jun-2010 | Current |
Mullothu Krishnakumar ![]() | Director | 11-Jun-2010 | Current |
Renolife Pharma (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.19% increase. The company also saw a substantial fall in profitability, with a 13.64% decrease in profit. The company's net worth Soared by an impressive increase of 15.73%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
In 2023, Renolife Pharma (India) had a promoter holding of 71.51% and a public holding of 28.49%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Tirunilayi Venugopal and Pudugrammam Vaidyanathan are mutual person
Pudugrammam Vaidyanathan is a mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Renolife Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Renolife Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renolife Pharma (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Renolife Pharma (India) Private Limited last Annual general meeting of members was held on 28 Sep 2023 as per latest MCA records.
Renolife Pharma (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Ernakulam.
Tirunilayi Krishnan Venugopal was appointed as a Director was appointed as a Director on 11 Jun 2010 & has been associated with this company since 14 years 8 months .
Pudugrammam Krishna Iyer Vaidyanathan was appointed as a Director was appointed as a Director on 11 Jun 2010 & has been associated with this company since 14 years 8 months .
Ajitkumar Warrior was appointed as a Director was appointed as a Director on 11 Jun 2010 & has been associated with this company since 14 years 8 months .
Shaji Thuvakkunnon was appointed as a Director was appointed as a Director on 11 Jun 2010 & has been associated with this company since 14 years 8 months .
Renolife Pharma (India) Private Limited was incorporated on 10 Nov 2008.
The authorized share capital of Renolife Pharma (India) Private Limited is ₹ 1.10 M and paid-up capital is ₹ 1.05 M.
Currently 7 directors are associated with Renolife Pharma (India) Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Renolife Pharma (India) Private Limited is Rhine House 21/555(2) Adithyanagar East Vennakkara, Nurani Post, Kerala, India, 678004.
The corporate identification number (CIN) of Renolife Pharma (India) Private Limited is U52310KL2008PTC023384 and the company number is 023384 as per Ministry of Corporate Affairs (MCA).
According to the financial reports for the fiscal year 2023, the revenue trend for Renolife Pharma (India) Private Limited has risen by 18.19%.
The financial reports for the fiscal year 2023 indicates that The net worth of Renolife Pharma (India) Private Limited has experienced an upsurge of 15.73%.
The most recent Balance Sheet for Renolife Pharma (India) Private Limited was filed with the ROC on 31 Mar 2023.
UP